Search Results for “Retinitis pigmentosa” - Page 10

Meet our volunteers: Martin Hills

Martin started volunteering for Retina UK in 2014 after retiring as a Chartered Civil Engineer.

Light sensing small molecule given green light

Biotechnology company Kiora Pharmaceuticals has been given the go-ahead to start in-human testing of a novel “small molecule” treatment, known as KIO-301, for advanced vision loss in retinitis pigmentosa (RP). The phase 1b clinical trial will take place in Adelaide, Australia, and will begin enrolling participants towards the end of 2022.

Retina UK awards new research funding

Retina UK is delighted to have awarded a new three-year research grant to Prof Majlinda Lako at Newcastle University for a project entitled: To establish AAV.PRPF31 gene augmentation in PRPF31-deficient RPE and photoreceptor cells and assess its efficacy in restoring RPE and photoreceptor function.

Gene therapy shows promise in tackling X-linked RP

Early results from clinical testing of a gene therapy to treat X-linked retinitis pigmentosa (XLRP) have shown partial reversal of sight loss in some patients.

Blindingly chatty podcast header with two speech bubbles and a visual representation of audio below

Podcast: Blindingly Chatty – episode two

In this episode Laura and Mark talk about their dreams and how they see the world in sleep. Mark is living with retinitis pigmentosa so his sight has deteriorated over his life, whereas Laura lost her sight at a very young age. They also briefly cover Charles Bonnet Syndrome (CBS).

e-Newsletter October 2023

Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.

Vitamin A spelled out in orange round capsules

Vitamin A supplements provides no vision benefit to RP patients

Research determines that taking high dose vitamin A supplements does not slow vision loss in people with retinitis pigmentosa (RP).

News

Helpline

Search